LONDON, Jan 24 (Reuters) - GlaxoSmithKline said onFriday the first of its phase three studies into the combinationof Tafinlar and Mekinist to treat melanoma, the deadliest formof skin cancer, had met its main goal.
The results, along with further data expected from thestudy, will increase the body of evidence on the safety andefficiacy of the combination, the British company said.
The combined use of Tafinlar, also known as dabrafenib, andMekinist, or trametinib, was given the green light from the Foodand Drug Administration (FDA) in the U.S. earlier this month.